Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Benitec May Change HCV Paradigm Again With Single-Dose, DNA-Directed RNAi

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Australian biotech recently got FDA authorization to move its first (dd)RNA candidate, TT-034, into clinical development for hepatitis C. Dosing in a 14-patient, five-cohort, Phase I/IIa study will begin in mid-March and produce final data in about 18 months.


Related Content

Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts